Elevated tumor necrosis factor-α activation of human immunodeficiency virus type 1 subtype C in southern Africa is associated with an NF-κB enhancer gain-of-function

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 76-81

  Montano, Monty A ^a   Nixon, Christian P ^a   Ndung'u, Thumbi ^a   Bussmann, Hermann ^a   Novitsky, Vladimir A ^a   Dickman, Dorothy ^a   Essex, Max ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DNA FLANKING REGION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SOUTH AFRICA; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS TRANSCRIPTION;

BINDING SITES; BOTSWANA; ENHANCER ELEMENTS (GENETICS); HIV INFECTIONS; HIV-1; HUMANS; NF-KAPPA B; TERMINAL REPEAT SEQUENCES; TRANS-ACTIVATION (GENETICS); TUMOR NECROSIS FACTOR-ALPHA; ZIMBABWE;

EID: 0033978536     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315185     Document Type: Article

References (42)

1. 1. Weniger BG, Takebe Y, Ou CY, Yamazaki S. The molecular epidemiology of HIV in Asia. AIDS 1994;8:S13-28.
2. 2. Stanecki KA, Way PO. AIDS in the world. New York: Oxford Press, 1996.
3. 3. Mertens T, Piot P. Global aspects of human immunodeficiency virus epidemiology: general considerations. In: de Vita VT Jr, Hellman SA, Rosenberg SA, Curran J, Essex M, Fauci AS, eds. AIDS: etiology, diagnostics, treatment, and prevention. New York: Lippincott-Raven, 1997:103-18.
4. 4. Janssens W, Buve A, Nkengasong JN. The puzzle of HIV-1 subtypes in Africa. AIDS 1997;11:705-12.
5. 5. World Health Organization. Report on the global HIV/AIDS epidemic - June 1988. Geneva, Switzerland: United Nations Programme on HIV/AIDS and WHO, 1988.
6. 6. Tscherning C, Alaeus A, Fredrikson R, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998;241: 181-8.
7. 7. Li-Hua P, Nelson JAE, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol 1999;73: 6271-81.
8. 8. Björnal Å, Sönnerborg A, Tschering C, Albert J, Fenyö EM. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses 1999;15: 647-53.
9. 9. Neilson JR, John GC, Carr JK, et al. Subtypes of HIV-1 and disease stage among women in Nairobi, Kenya. J Virol 1999;73:4393-403.
10. 10. Zijenah L, Mbizvo MT, Kasule J, et al. Mortality in the first 2 years among infants born to human immunodeficiency virus-infected women in Harare, Zimbabwe. J Infect Dis 1998;178:109-13.
11. 11. Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 1992;6:347-63.
12. 12. Blackwood EM, Kadonaga JT. Going the distance: a current view of enhancer action. Science 1998;281:61-3.
13. 13. Herr W, Clarke J. The SV40 enhancer is composed of multiple functional elements that can compensate for one another. Cell 1986;45:461-70.
14. 14. Dynan WS. Modularity in promoters and enhancers. Cell 1989;58:1-14.
15. 15. Chen BK, Feinberg MB, Baltimore D. The κB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J Virol 1997;71:5495-504.
16. 16. Ross E, Buckler-White A, Rabson A, Englund G, Martin M. Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol 1991;65:4350-8.
17. 17. Zhang L, Huang Y, Yuan H, Chen B, Ip J, Ho D. Identification of a replication-competent pathogenic human immunodeficiency virus type 1 with duplication in the TNF-1 alpha region but lacking NF-κB binding sites. J Virol 1997;71:1651-6.
18. 18. Salminen MO, Johansson B, Sonnerborg A, et al. Full-length sequence of an Ethiopian human immunodeficiency type 1 (HIV-1) isolate of genetic subtype C. AIDS Res Hum Retroviruses 1996;12:1329-39.
19. 19. Gao F, Robertson DL, Morrison SG, et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996;70:7013-29.
20. 20. Montano MA, Novitsky VA, Blackard JT, Cho ML, Katzenstein DA, Essex M. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J Virol 1997;71:8657-65.
21. 21. Montano M, Nixon C, Essex M. Dysregulation through the NF-κB enhancer and TATA box of the HIV-1 subtype E promoter. J Virol 1998;72:8446-52.
22. 22. Matsuyama T, Nobuyuki K, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-17.
23. 23. Lahdevirta J, Maury CP. Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-91.
24. 24. Antoni B, Rabson A, Kinter A, Bodkin M, Poli G. NF-kappa B -dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology 1994;202:684-94.
25. 25. Osborn L, Kunkel S, Nabel G. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci USA 1989;86:2336-40.
26. 26. Sha BE, D'Amico RD, Landay AL, et al. Evaluation of immunological markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunological response to HIV in the female genital tract. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:161-8.
27. 27. Anderson DJ, Politch JA, Tucker LD, et al. Quantilation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. AIDS Res Hum Retroviruses 1998;14(Suppl 1):S43-9.
28. 28. Ho J, He S, Hu A, et al. Neutrophils from human immunodeficiency virus (HIV)-seronegative donors induce replication from HIV-infected patients' mononuclear cells and cell lines: an in vitro model of HIV transmission facilitated by Chlamydia trachomatis. J Exp Med 1995;181:1493-505.
29. 29. Plummer FA. Heterosexual transmission of HIV-1: interactions of conventional sexually transmitted diseases, hormone contraception, and HIV-1. AIDS Res Hum Retroviruses 1998;14 (Suppl 1):S5-10.
30. 30. Plummer F, Simonsen J, Cameron D, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991;163:233-9.
31. 31. Bassett MT, Mhloyi M. Women and AIDS in Zimbabwe: the making of an epidemic. Int J Health Serv 1991;21:143-56.
32. 32. Ghys P, Fransen K. Diallo M, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases, and immunosuppression in female sex workers in Abidjan. Cote d'Ivoire. AIDS 1997;11:F85-93.
33. 33. Novitsky VA, Montano MA, McLane MF, et al. Molecular cloning and phylogenetic analysis of HIV-1 subtype C: a set of 23 full-length clones from Botswana. J Virol 1999;73:4427-32.
34. 34. Marlink R, Kanki P, Thior K, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-90.
35. 35. Kanki PJ, Hamel DG, Sankale JL, et al. HIV-1 subtypes differ in disease progression. J Infect Dis 1999;179:68-73.
36. 36. Adjorlolo-Johnson G, DeCock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994;272:462-6.
37. 37. Kanki PJ, Travers K, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-6.
38. 38. Hannibal M, Markovitz D, Clark N, Nabel G. Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals. J Virol 1993;67:5035-40.
39. 39. Verhoef K, Sanders R, Fontaine V, Kitajima S, Berkhout B. Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-κB enhancer element into a GABP binding site. J Virol 1999;73:1331-40.
40. 40. Patterson BK, Landay A, Andersson J, et al. Repertoire of chemokine receptor expression in the female genital tract. Am J Pathol 1998;153: 481-90.
41. 41. Daelemans D, Vandamme AM, De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antivir Chem Chemother 1999;10:1-14.
42. 42. Tutter A, Jones KA. Chemicals that footprint DNA: hitting HIV-1 in the minor groove. Proc Natl Acad Sci USA 1998;95:12739-41.